Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

* Participant must have skin lesions that are diagnostic of Hidradenitis Suppurativa (HS) for at least 1 year (365 days) prior to the Baseline visit * Participant must have at least 3 distinct anatomical regions involved with inflammatory (also termed 'active') HS lesions; plus * either one axilla or one inguinal region (limited to the inguino-crural fold and adjacent areas) that requires excisional surgery, and * with at least one of the other affected HS regions (e.g., contralateral inguinal region, buttocks, inframammary region) rated as Hurley Stage II or III * Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit within the HS non-surgical sites * The HS surgical site must contain at least one active HS lesion * The HS surgical site must require excisional surgery and is large enough to require healing by secondary intention as assessed by the designated surgeon

* Participant has a draining fistula count of greater than 20 at the Baseline visit * Participant requires surgery at any anatomical site other than an unilateral axilla or inguinal region site * Participant requires surgical management prior to Week 13 * Participant requires, based on the designated surgeon's assessment, excisional surgery with primary closure as the method of closure being most beneficial for the participant